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Abstract
Background: There is growing awareness that tumour cells build up a ‘‘self-advantageous’’ microenvironment that reduces
effectiveness of anti-tumour immune response. While many different immunosuppressive mechanisms are likely to come
into play, recent evidence suggests that extracellular adenosine acting at A2A receptors may have a major role in down-
modulating the immune response as cancerous tissues contain elevated levels of adenosine and adenosine break-down
products. While there is no doubt that all cells possess plasma membrane adenosine transporters that mediate adenosine
uptake and may also allow its release, it is now clear that most of extracellularly-generated adenosine originates from the
catabolism of extracellular ATP.
Methodology/Principal Findings: Measurement of extracellular ATP is generally performed in cell supernatants by HPLC or
soluble luciferin-luciferase assay, thus it generally turns out to be laborious and inaccurate. We have engineered a chimeric
plasma membrane-targeted luciferase that allows in vivo real-time imaging of extracellular ATP. With this novel probe we
have measured the ATP concentration within the tumour microenvironment of several experimentally-induced tumours.
Conclusions/Significance: Our results show that ATP in the tumour interstitium is in the hundrends micromolar range,
while it is basically undetectable in healthy tissues. Here we show that a chimeric plasma membrane-targeted luciferase
allows in vivo detection of high extracellular ATP concentration at tumour sites. On the contrary, tumour-free tissues show
undetectable extracellular ATP levels. Extracellular ATP may be crucial for the tumour not only as a stimulus for growth but
also as a source of an immunosuppressive agent such as adenosine. Our approach offers a new tool for the investigation of
the biochemical composition of tumour milieu and for development of novel therapies based on the modulation of
extracellular purine-based signalling.
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Introduction
While it is well established that ATP is an ubiquitous
extracellular messenger, simple and reliable techniques to measure
its concentration in the interstitium are missing. A few years ago
Dubyak and co-workers [1] showed that a protein-A-luciferase
chimera is a suitable probe of pericellular ATP in cells sensitized
with IgG, and more recently Dale and Gourine have introduced a
biosensor technique [2,3]. These measurements clearly demon-
strated that the concentration of ATP in the pericellular space is at
least ten-fold higher than in the bulk solution and may reach tens
of micromoles/liter. However, it would be of great biological
interest to exploit the strong luciferase-dependent luminescence to
image extracellular ATP in vivo. This might be especially valuable
for a deeper understanding of tumour-host interactions, as it is
increasingly appreciated that tumours build up a specific
microenvironment that affects crucially host immune response
and cancer cell proliferation and dissemination [4,5].
Recent data show that adenosine concentration is much higher
in the interstitium of solid tumours compared to healthy tissues [6],
an observation with far-reaching implications given the immuno-
suppressive activity of this ATP metabolite [6,7]. Although most
cells express adenosine transporters, there are few doubts that a
main source of extracellular adenosine is hydrolysis of extracellular
ATP by cell surface ecto-ATPases [8,9]. Thus, it would be of
interest to be able to monitor in real time extracellular ATP levels
in healthy and diseased tissues. To this aim, we have engineered a
chimeric luciferase-folate receptor construct in which the luciferase
cDNA was appended to targeting sequences (leader sequence and
GPI anchor) derived from the folate receptor [10]. The chimeric
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2599protein is targeted to, and retained at the plasma membrane thus
detecting ATP in the aqueous layer close to the cell surface.
We have now used this novel probe, named pmeLUC (plasma
membrane luciferase), to generate stably transfected HEK293 cells
(HEK293-pmeLUC cells) that act as in vivo sensors of the ATP
concentration in the tumour microenvironment.
Results
We anticipated that HEK293-pmeLUC cells might function as
in vivo reporters of the interstitial ATP concentration in healthy
and diseased tissues. As shown in figure 1, i.v. inoculation of
HEK293-pmeLUC cells in healthy nude mice caused a modest,
barely detectable, increase in luminescence, except for the third
mouse from the left, which showed a strong signal at site of
injection in the tail, likely due to tissue damage and ATP release
during the injection. The tail luminescence signal gradually
disappeared, and for up to 42 days no additional luminescence
foci appeared throughout the body in any of the mice, whether
imaged in a dorsal (figure 1A) or abdominal (figure 1B) projection.
In three experiments involving 10 mice, we observed a faint,
transient abdominal luminescence only in two animals. HEK293-
pmeLUC cells were then i.p. inoculated (figure 2A). In this case
also no significant light emission was detected for up to 24 days of
observation. These experiments show that HEK293-pmeLUC
cells do not detect significant extracellular ATP levels when
inoculated i.v. or i.p. into healthy animals, unless tissue damage
occurs, as shown by the single mouse in figure 1A.
However, it may well be that this failure is due to unsuitability of
HEK293-pmeLUC cells to report extracellular ATP in vivo. To
clarify this issue, we inoculated HEK293-pmeLUC cells into mice
bearing the OVCAR-3 human ovarian carcinoma (figure 2B). In
tumour-bearing mice luminescence was very bright shortly after
i.p. inoculation (first image was acquired 15 sec after injection, not
shown), likely signalling the ATP-rich inflammatory environment
within the peritoneal cavity, then attenuated slightly and localized
to discrete abdominal foci (figure 2B). At day 16 after injection,
mice were sacrificed and subjected to post-mortem analysis.
Luminometric examination of the peritoneal cavity revealed
dissemination of numerous light-emitting metastasis throughout
the peritoneum (figure 3A). To identify the cell types present in the
metastasis, some of the peritoneal masses were excised (figure 3B),
and subjected to histological analysis (figure 3C), which revealed
the typical morphology of an ovarian carcinoma. To further
characterize the cell types present, the tumour masses were
homogenized, stained with Abs raised against either luciferase (to
detect HEK293-pmeLUC cells) or the OVCAR-3-specific antigen
CD51 (to detect ovarian carcinoma cells), and analyzed by
cytofluorimetry (figure 3D). As a final proof of the presence of
infiltrating HEK293-pmeLUC cells within the tumour masses,
tumour homogenates were assayed for the presence of pmeLUC
message (figure 3E). The pmeLUC message was very abundant in
the tumour masses (figure 3E, lane 3). As controls we run samples
from cultured HEK293-pmeLUC cells, which showed a signal of
intensity comparable to that of tumours homogenates, and from
cultured OVCAR-3 cells, which were not surprisingly negative for
pmeLUC expression. This is unequivocal proof that HEK293-
pmeLUC cells infiltrate the OVCAR-3 tumour masses.
These experiments provide three valuable pieces of information:
a) the ATP concentration in the extracellular environment is very
low in healthy tissues, certainly below the threshold for HEK293-
pmeLUC detection (about 1–5 mM); b) HEK293-pmeLUC cells
infiltrate ovarian carcinoma growing in the peritoneal cavity and
report ATP in the tumour microenvironment; c) light emission
from tumours is very bright, close to saturation of the luciferase
signal, thus the intratumour extracellular ATP concentration must
be orders of magnitude higher than that in the healthy tissue.
However, there are some important caveats. Exogenous cancer
cells are known to chemotact towards, infiltrate and even
proliferate within tumour masses [11], thus it is possible that the
strong luminescence signal detected in the ovarian carcinoma-
bearing mice is not due to the increased ATP concentration in the
tumour microenvironment, but rather to the increased local
density of HEK293-pmeLUC cells. If this were the case, the
higher local luciferase concentration would certainly cause
Figure 1. Imaging of healthy nude mice i.v. injected with
HEK293-pmeLUC cells. Mice were injected i.v. with 2610
6 HEK293-
pmeLUC cells. D-luciferin was administred intraperitoneally. Images
were captured 15 minutes after D-luciferin administration. Acquisition
time was 3 min, and images were acquired over 2 months every 2 days
both from the dorsal (A) and the ventral (B) view. The earliest time point
was at 15 min after D-luciferin injection. Only images taken after 1, 3, 15
and 42 days are shown.
doi:10.1371/journal.pone.0002599.g001
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same amount of HEK293-pmeLUC cells (2610
6) s.c. into an
established MZ2-MEL human melanoma, or controlateral healthy
tissue. Under these conditions, since the local tissue concentration
of luciferase is the same at both sites, changes in light emission
should reflect only differences in ATP levels. As shown in
figure 4A, light emission, which was very strong from both sites
1 day after injection, increased steadily from the tumour-bearing
side, while progressively faded from the healthy side (compare day
3 to 1), to disappear completely at day 10. It is very likely that the
initial luminescence signal originating from both sites was due to
the injection trauma, as clearly shown in figure 1. As tissue injury
healed, luminescence decreased in the healthy but not tumour-
bearing site, indicating a stable, higher interstitial ATP level, in
agreement with the experiments shown in figure 2.
However, it might be objected that although the same amount
of cells are inoculated into the tumour and the healthy tissue,
HEK293-pmeLUC are retained longer at the site of intratumour
injection, while on the contrary they might migrate away from the
site of injection when inoculated into healthy tissue. This would
lead to a dilution of the luciferase signal from the healthy tissue.
To rule out this possibility, we engineered HEK293 cells with a
luciferase construct encoding a luciferase lacking the plasma
membrane-targeting sequence, and therefore localized in the
cytosol (HEK293-cytLUC). This luciferase monitors intracellular
but is insensitive to extracellular ATP. FACS analysis showed that
HEK293-cytLUC and HEK293-pmeLUC express luciferase to
the same level (figure 5, A and B), thus they allow a careful
comparison of luminescence emission. As shown in figure 4B,
HEK293-cytLUC emitted a strong, long lasting, light signal from
Figure 2. Imaging of tumour-bearing nude mice injected with HEK293-pmeLUC cells. (A) Healthy nude mice were injected i.p. with 2610
6
HEK293-pmeLUC cells and monitored for 3 months (only 4 time points are shown). (B) Nude mice were injected i.p. with the human ovarian
carcinoma cell line OVCAR-3 (1.5610
6). Twenty days post-implantation, HEK293-pmeLUC cells (2610
6) were i.p. injected, followed by D-luciferin.
OVCAR-3-bearing mice were monitored over 16 days, and were then euthanized according to bioethical regulations.
doi:10.1371/journal.pone.0002599.g002
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with HEK293-pmeLUC, the signal from healthy tissue injected
with HEK293-cytLUC did not disappear and was still very strong
at day 10, indicating that inoculated cells were retained close to the
site of injection. To further validate HEK293-pmeLUC cells as
ATP reporters, we tested their sensitivity to the ATP-hydrolyzing
enzyme apyrase. Apyrase was injected into the tumour site 4 days
after HEK293-pmeLUC cells, and luminescence emission mon-
itored during 48 h (figure 6). We anticipated that if HEK293-
pmeLUC cells were faithful indicators the extracellular ATP levels,
apyrase injection should cause a drop in luminescence. This was
indeed the case, as shown by imaging (figure 6, A and B) and
quantitative photon counting of the region-of-interest (figure 6C).
Luminescence emission was decreased by apyrase by about 50%,
and recovered steadily to pre-apyrase levels within 2 days, likely as
a consequence of enzyme diffusion from or inactivation at the
injection site. Vehicle injection on the contrary caused as expected
a damage-induced luminescence increase. Finally, we performed
an in vitro calibration of HEK293-pmeLUC cell luminescence with
the IVIS luminometer which indicated an ATP concentration in
the tumour interstitium in the hundred micromolar range, or
possibly higher, as the signal saturated above 700 mM ATP
(figure 7).
Discussion
There is growing awareness that the tumour microenvironment
has a key role in supporting tumour growth and in dictating the
rules of host-tumour interaction [12,5]. The tumour may wield
host response by inducing the formation of protected niches that
allow survival of cancer stem cells and their differentiation into
mature cancer cells [13]. The tumour microenvironment which
Figure 3. HEK293-pmeLUC cells localize to tumour foci. (A) Mice were euthanized, the peritoneal cavity was opened and imaged. (B) Single
tumour foci were excised and luminescence recorded. (C) Tissue section from one of the tumour foci stained with haematoxylin/eosin. (D)
Cytofluorimetric analysis of cells isolated from tumour foci. Staining was performed with monoclonal FITC-labeled rabbit anti-luciferase (red trace on
the left panel) or anti-CD51 (red trace on the right panel) Abs. Irrelevant IgG1 Ab (grey trace on both the right and left panel) was used as control. (E)
Expression of pmeLUC mRNA in tumour foci excised from mice injected with OVCAR-3 and HEK293-pmeLUC cells. OVCAR-3 and HEK293-pmeLUC
cells grown in culture are shown as controls. RT-PCR was performed as described in Materials and Methods.
doi:10.1371/journal.pone.0002599.g003
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responsible for creating conditions that hinder the effectiveness of
the host immune response and lead to immunoevasion, or even to
tumour progression [14]. The biochemical composition of the
tumour microenvironment is poorly known, but it is understood
that it may profoundly change depending on tumor type and the
host immunocompetence [15].
Depending on the tight balance between tumour-induced or
tumour-released immunosuppressive factors and host-derived
immunoactivating factors the microenvironment creates favour-
able or unfavourable conditions for tumour growth. This generates
a network of facilitating or inhibitory interactions the effect of
which is extremely difficult to anticipate. In this context hypoxic
conditions that characterize several tumours may be an important
component of the mechanism of tumour protection. Hypoxia
causes the activation of hypoxia-inducible factor 1 a (HIF-1a) and
accumulation of extracellular adenosine. Both factors are in
principle very important in supporting tumour growth as HIF-1a
controls angiogenesis and adenosine exerts a profound immuno-
suppressive activity, thus protecting the tumour from inflamma-
tory cells. Recent data show that solid tumours have a gradient of
adenosine concentration from the centre to the periphery, higher
than the surrounding healthy tissue [6]. In addition, many
tumours over-express enzymes involved in the catabolism of
extracellular nucleotides and in the generation of adenosine [16].
Furthemore, glioblastoma cells injected in vivo together with
apyrase show a reduced ability to produce tumours [17].
Accumulation of adenosine into the tumour microenvironment
does not only protect tumour cells from the immune response, but
may also exert a trophic effect on the tumour itself by stimulating
endothelial cell proliferation and angiogenesis [18,19,20].
Although cells express carriers that may mediate adenosine
translocation into the extracellular milieu, most extracellular
adenosine is generated at the expenses of extracellular ATP via
Figure 4. Comparison of luminescence emission from HEK293-pmeLUC and HEK293-cytLUC cells injected into MZ2-MEL melanoma
and healthy tissue. Nude mice were inoculated with MZ2-MEL cells in the right dorsal hip. After about 20 days, when the tumour was about 1–
1.561–1.5 cm size, HEK293-pmeLUC (A) or HEK293-cytLUC (B) cells were injected s.c. into the tumour bearing (right) or healthy (left) site.
doi:10.1371/journal.pone.0002599.g004
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[21,22]. However, ATP in the tumour microenvironment is
important not only as a source of adenosine but also for its intrinsic
activity. In fact ATP itself modulates inflammation by triggering
IL-1 maturation and release, dendritic cell differentiation by
inducing a Th2-skewing phenotype and cell proliferation or cell
death, depending on the concentrations and the activation of
individual P2 receptors [23]. In addition, its has been recently
shown that ATP causes shedding of metalloproteases (MMP9) [24]
and expression of indoleamine oxygenase [25]; both activities may
be very relevant for tumour progression as MMP9 release
facilitates tumour invasion while indoleamine oxygenase has
immunosuppressive activity.
Bioluminescence imaging is increasingly recognized as a
powerful tool to study in vivo transcriptional regulation, signal
transduction, activation of cancer-specific genes. So far, luciferase
has been almost exclusively used as an intracellular reporter, to
monitor the activity of specific transcriptional activators such as for
example the estrogen receptor [26] or NF-kB [27]. In this study
we show that cells engineered with luciferase can be also used to
probe the extracellular space and to analyze the biochemical
composition of the tumour microenvironment. Furthermore, since
an increased ATP concentration is a feature of inflammation,
engineering inflammatory cells with pmeLUC will make possible
in vivo imaging of inflammation. Finally, since appending proper
target sequences to luciferase may allow targeting to specific
regions of the plasma membrane, we anticipate that pmeLUC
may even allow to probe changes in the extracellular ATP
concentration at restricted sites of cell-to-cell interaction.
Materials and Methods
Cell lines
Human embryonic kidney cells (HEK293) were purchased from
the American Type Culture Collection (Rockville, MA, USA).
Cells were cultured in Dulbecco’s modified eagle medium
(DMEM) (Sigma Aldrich, Milano, Italy) supplemented with 10%
fetal bovine serum (FBS), penicillin G (50 units/ml), and
streptomycin sulfate (50 mg/ml). The OVCAR-3 human ovarian
carcinoma and MZ2-MEL human melanoma cell lines (purchased
from Dr. T. Boon, Ludwig Institute for Cancer Research, Brussels,
Belgium), were grown as a monolayer at 37uC in a humidified 5%
CO2 atmosphere in RPMI 1640 (Life Technologies, Grand Island,
NY) supplemented with 10% FBS, penicillin G (50 units/ml), and
streptomycin sulfate (50 mg/ml) (Sigma).
Luciferase constructs
Targeting of luciferase to the extracellular aspect of the plasma
membrane (pmeLUC) was achieved by adding to luciferase cDNA
a N-terminal endoplasmic reticulum import sequence (leader
sequence), and a C-terminal glycophosphatidylinositol anchor
sequence (GPI sequence) of the human folate receptor. These
minimal targeting and anchor signals allow localization of
luciferase on the outer side of the plasma membrane. The
luciferase used was Photinus pyralis luciferase modified for
optimizing transcriptional activity in eukaryotic cells (Promega
Italia SrL, Milano, Italy). Luciferase cDNA was amplified from a
modified pGL3-control plasmid (kind gift of Dr Guy Rutter,
University of Bristol, UK) using the following primers 59 -C C C
TGC AGA TGG AAG ACG CCA AAA ACA TAA AGA AAG
G-3 9 (corresponding to the sequence encoding amino acids 1–9 of
luciferase; PstI site underlined) and 59 -G CT GCA GCC ACG
GCG ATC TTT CCG CCC TTC TTG G - 39 (including amino
acids 542–549 of luciferase cDNA without the stop codon; PstI site
underlined). The PCR product was transferred to pBSK+ vector
(Agilent-Stratagene, Santa Clara CA, USA), digested with the
enzyme PstI and inserted in right frame between a PstI fragment
encoding the complete N–terminal leader sequence of the human
folate receptor (26 aa) fused with myc tag (10 aa) and a PstI
fragment of the GPI anchor protein (28 aa), to generate the
pmeLUC construct. The whole final construct was excised by a
NotI/XhoI or XbaI digestion, and cloned into the expression vectors
pcDNA3 or VR1012, as described previously (10).
Figure 5. Luciferase expression by HEK293-pmeLUC and
HEK293-cytLUC. Plasma membrane (A) or cytosolic (B) luciferase
expression was analyzed with a specific anti-luciferase Ab (see Figure 3).
An isotype-matched control mAb was used as control. Luciferase
expression is reported as percentage of positive cells.
doi:10.1371/journal.pone.0002599.g005
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pGLP3-basic vector (Promega) modified by insertion of cytomeg-
alovirus promoter excised from a pcDNA3 vector (Invitrogen SrL
Milano, Italy).
Transfection of HEK293 cells and stable clones selection
HEK293 transfection with plasma membrane-targeted lucifer-
ase (pmeLUC) or cytosolic luciferase (cytLUC) was carried out
with Lipofectamine 2000 (Invitrogen, San Giuliano Milanese,
Italy). Selection was performed in the presence of G418 as
previously described [10].
Real time in vivo imaging
In vivo bioluminescent imaging was performed with a ultra low-
noise, high sensitivity cooled CCD camera, mounted on a light-
tight imaging chamber (IVIS 100 System
TM, Xenogen, Roissy,
France). Tracking, monitoring and quantification of signals were
controlled by the acquisition and analysis software Living ImageH
(Xenogen). After cell inoculation, 150 mg/kg D-luciferin was i.p
administered (3 mg/mouse), and the luminescence was captured
from both dorsal and ventral views. D-luciferin was administered
to anesthetized (1–3% isoflurane) animals 15 minutes before
image acquisition. Anesthetized mice were then placed in the
IVIS
TM Imaging System and imaged. Three-four mice were
imaged at each time. Regions of interest from displayed images
were identified around the tumor sites and were quantified as total
photon counts or photons/s using the Living ImageH software. For
i.v. inoculation, cells (2610
6/mouse) from a stable HEK293-
pmeLUC clone were slowly injected into the tail vein of 5–6 weeks
old athimic nude (nude/nude) mice. Animals were monitored every
3–4 days. For i.p. inoculation, nude mice were injected with
1.5610
6 OVCAR-3 cells suspended in 200 ml of FBS-free RPMI
medium followed by i.p. inoculation of HEK293-pmeLUC cells
(2610
6/mouse). Tumour-free nude mice were also inoculated with
HEK293-pmeLUC cells as a control. Luminescence was moni-
tored every 2 days for up to 16 (OVCAR-3 bearing mice injected
with HEK293-pmeLUC) or 90 days (control mice). Tumour-
bearing mice were sacrificed after 16 days according to bioethical
regulations. For s.c. inoculation, a melanoma xenograft was
induced on the right dorsal hip of nude mice by a injection of
8610
6 MZ2-MEL cells. Fifteen–twenty days after tumor inocu-
lation, when the melanoma had reached a size of 1,561,5 cm,
Figure 6. Sensitivity of HEK293-pmeLUC cells to apyrase. A melanoma was induced as described in Figure 4, and inoculated with HEK293-
pmeLUC cells 20 days after implant. Apyrase (20 U in 40 ml of serum free DMEM ) or vehicle (serum free DMEM) was injected into the tumour four
days later. Bioluminescence was recorded as indicated. (A) Apyrase-injected, or (B) vehicle-injected mice. (C) Quantitative analysis of light emission
from region-of-interest. Data are averages of measurements from 4 mice (n=4). * p,0.05 (paired t-test).
doi:10.1371/journal.pone.0002599.g006
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in the left tumour-free, dorsal hip (control), and in the melanoma-
bearing right dorsal hip. Mice were imaged every 2 days. Strict
animal care procedures were in accordance with institutional
guidelines in compliance with national and international laws and
policies (European Economic Community Council Directive 86/
109, OJL 358, Dec. 1, 1987 and NIH Guide for the Care and Use
of Laboratory Animals). Mice used in these studies were 5- to 6-
week-old nude/nude mice, weighing 18 to 25 g, purchased from
Harlan Laboratories (Udine, Italy) and housed in sterile enclosures
under specific virus and antigen-free conditions.
In vitro and ex vivo imaging
For in vitro imaging, 7610
4 HEK293-pmeLUC cells were
seeded into 12-well plates (Becton Dickinson Biosciences, Franklin
Lakes, NJ, USA). 60 mg/well of D-luciferin (Xenogen) was added
to each well 30 min before imaging. Imaging time was 3 min/
plate. For ex vivo imaging, mice were handled as described above
and no further luciferin was injected into the mice before
necropsy. Tissues of interest were excised, placed into 10 cm
tissue culture plate and acquired for 3 minutes. Tissues were then
fixed in 10% formalin (Sigma) and subjected to histology.
Histology
To confirm the presence of HEK293-pmeLUC, tumour mass
were excised from the mice at necropsy and imaged right away.
After bioluminescent analysis, tissue samples were fixed in 10%
formalin solution (Sigma Aldrich) and embedded in paraffin. For
histology, 5 mm thick sections were cut from formalin fixed,
paraffin embedded, blocks and stained with hematoxylin/eosin.
Analysis of pmeLUC/mRNA Expression
Total RNA was extracted with RNAspin Mini Isolation Kit (GE
Healthcare, Milano, Italy) from OVCAR-3 cells (as a negative
control), HEK293-pmeLUC stable clone (as positive control), and
OVCAR-3 xenografts from mice inoculated with HEK293-
pmeLUC. Primers for pmeLUC were the following: forward 59-
ATATGTGGATTTCGAGTCGTC-39 and reverse 59-GATG-
GATTCCAATTCAGCGGG-39 (PCR product, 597 bp). To
obtain cDNA, 200 ng of total RNA were transcribed with Access
RT-PCR System (Promega, Milano, Italy). RT-PCR was
performed using 10 ml of buffer AMV/Tfl Reaction buffer,
30 mlH 2O DNAse/RNAse free, 2 ml of each primer (final
concentration 20 picoM each), and 2 ml of MgSO4 (stock,
25 mM). Retrotranscription conditions were: 2 min at 95uC, then
1 cycle of 48uC for 55 min and 2 min at 95uC. Thirty five cycles of
amplification followed: 94uC for 1 min, 56uC for 1 min, 72uC for
2 min), and a final elongation at 72uC for 8 min. PCR products
were resolved by electrophoresis on a 1% agarose gel.
Flow cytometry
For staining of intracellular luciferase (cytLUC), cells were fixed
with 2% paraformaldehyde (Sigma Aldrich) at room temperature
for 20 min, rinsed twice with permeabilization buffer (PBS, 1%
FBS, 0.1% saponin; Sigma Aldrich), and incubated with a
luciferase specific mAb (8–10 mg/5610
5 cells) (Abcam, Cam-
bridge, UK) or an irrelevant mouse IgG1 (Serotec, Oxford, UK).
Cells were then washed twice with permeabilization buffer,
incubated with FITC-conjugated F(ab’)2 fragments of rabbit
anti-mouse IgG antibodies, washed twice in permeabilization
buffer and resuspended in staining buffer before being analyzed by
flow cytometry with a FACScan instrument (Becton Dickinson
Biosciences). For surface staining, cells isolated from OVCAR-3 i.
p. xenografts of mice inoculated with HEK293-pmeLUC were
incubated with an optimal amount of luciferase specific mAb or
with anti-CD51 (1 mg/5610
5 cells) (Becton Dickinson Bioscienc-
es). The primary antibody incubation was followed by an optimal
amount of secondary antibody incubation (FITC-conjugated
F(ab’)2 fragments of rabbit anti-mouse Ig antibodies). Stained cells
were analyzed by flow cytometry. Isotype- and subclass-matched
mouse Ig were used as negative controls in all the experiments at a
Figure 7. In vitro calibration of HEK293-pmeLUC biolumines-
cence. (A) HEK293-pmeLUC cells, 7610
4 per well, were incubated in
DMEM medium and challenged with increasing concentrations of
extracellular ATP and luminescence acquired with the IVIS luminometer
for 1 min. In (B) luminescence (total flux expressed as photon per sec)
was expressed as a function of the ATP concentration. Control well
contained only DMEM medium. D-luciferin was added to all wells at a
concentration of 60 mg/ml.
doi:10.1371/journal.pone.0002599.g007
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Dickinson Biosciences) was used for data analysis.
Statistical analys
Statistical analysis was performed using the Stat View software
package (SAS Institute Inc, Cary, NC, US). The data were
analysed by the Student t test for paired samples. Statistical
significance was assumed for p,0.05 (two tailed).
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